Syneos investor relations
Syneos Health
available free of charge on our website at investor.syneoshealth.com. Syneos Health assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with U.S. Generally Accepted
Syneos Health Schedules Second Quarter 2019 Earnings Call ...
Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com . To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States , approximately 15 minutes prior to the scheduled start time.
[PDF File]Syneos Health Fast Facts Sheet
https://info.5y1.org/syneos-investor-relations_1_4eb976.html
Syneos Health Fast Facts Sheet Who We Are Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through
[PDF File]December 18, 2018 - Global Biopharmaceutical Company
https://info.5y1.org/syneos-investor-relations_1_1c846b.html
Investor Relations Our Communities. Worldwide Facilities Workplace Policies . Priority Assessment GRI 102-41 Core Percentage of total employees covered by collective bargaining agreements Not Reported N – Information is not collected globally GRI 102-42 Core Basis for identification and selection of stakeholders with whom to engage
[PDF File]News Release IQVIA Reports Fourth-Quarter and Full-Year ...
https://info.5y1.org/syneos-investor-relations_1_4fe7d5.html
1 1 News Release Contacts: Andrew Markwick, IQVIA Investor Relations (andrew.markwick@iqvia.com) +1.973.257.7144 Tor Constantino, IQVIA Media Relations (tor.constantino@iqvia.com) +1.484.567.6732 IQVIA Reports Fourth-Quarter and Full-Year 2017 Results,
[PDF File]ANNUAL REPORT 2017
https://info.5y1.org/syneos-investor-relations_1_a02317.html
Index 01 Applus+ at a glance 04 07 Laboratories Division 58 02 Introduction: key pillars of our business 08 08 Automotive Division 66 03 Letter from the Chairman and the CEO
[PDF File]COMMERCIAL TRENDS CONSUMER DIGITAL MARKETING …
https://info.5y1.org/syneos-investor-relations_1_6e3efe.html
Syneos Health Consulting, 2018, Launch of the Future report Delivering on Patient-Centric Promise The customer base for medical affairs is much broader than the provider focus it had in the past. Payers and regulators are looking for proof of the medical, clinical and economic value of
[PDF File]Meg Alexander Managing Director Reputation & Risk ...
https://info.5y1.org/syneos-investor-relations_1_863a3c.html
Reputation & Risk Management Practice, Syneos Health Mark Corbae is a communications strategist and practitioner with more than 25 years of experience as a public relations agency executive and corporate staff professional. With a focus on the life sciences sector, Mark’s expertise includes corporate communications, investor relations, content
Zogenix to Present at Two Investor Conferences in April
Zogenix to Present at Two Investor Conferences in April March 25, 2019 EMERYVILLE, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor
INC Research/inVentiv Health Becomes Syneos Health
INC Research/inVentiv Health Becomes Syneos Health ... Investor Relations: Ronnie Speight Vice President, Investor Relations +1 919 745 2745 investor.relations@syneoshealth.com Press/Media: Danielle DeForge Senior Director, External Communications +1 202 210 5992 danielle.deforge@syneoshealth.com
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.